Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Mycosesarrow_drop_down
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Mycoses
Article . 2002 . Peer-reviewed
License: Wiley Online Library User Agreement
Data sources: Crossref
Mycoses
Article . 2003
versions View all 2 versions
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Voriconazol — Perspektiven und klinische Aspekte

Voriconazole — applications and perspectives
Authors: Markus Ruhnke;

Voriconazol — Perspektiven und klinische Aspekte

Abstract

Zusammenfassung. Der Wirkstoff von Vfend® ist Voriconazol, ein neues Antimykotikum aus der Gruppe der Triazole mit sehr breitem Wirkspektrum. Die Wirksamkeit wurde gegen Sproßpilz‐Arten wie Candida‐Species und Cryptococcus neoformans sowie gegen diverse Fadenpilze, insbesondere die Aspergillus‐Species, aber auch dimorphe Pilze in vitro und in vivo (in Tierexperimenten) nachgewiesen. In klinischen Phase‐II‐ und Phase‐III‐Studien konnte die Wirksamkeit insbesondere bei der oralen und ösophagealen Candidose sowie der akut invasiven und chronisch‐invasiven Aspergillose nachgewiesen werden. Das bisher bekannte Nebenwirkungsspektrum gleicht dem anderer Triazole, bis auf ein vermehrtes Auftreten von Sehstörungen. Für den Einsatz in der Therapie invasiver Mykosen stellt Voriconazol eine deutliche Bereicherung dar. In der Behandlung der akut invasiven Aspergillosen ist Voriconazol dem Amphotericin B‐Desoxycholat überlegen.Summary. Voriconazole (Vfend®) is a new broadspectrum antifungal agent belonging to the group of triazole drugs. In vitro and in vivo efficacy was demonstrated against a large variety of yeasts with excellent activity against all Candida species but as well against Cryptococcus neoformans. Furthermore, voriconazole has shown excellent activity against many moulds in particular against Aspergillus species, but endemic fungi such as Histoplasma capsulatum are in the spectrum as well. Clinical efficacy was demonstrated in several large phase II/III studies in diseases such as oral and oesophageal candidosis, acute invasive aspergillosis or chronic invasive aspergillosis. New adverse events such as visual disturbances has been described together with the use of voriconazole, but the majority of adverse events are similar to other triazole drugs and in particular not life‐threatening. With the introduction of voriconazole a great progress in the therapy of invasive fungal infections was achieved. In the therapy of invasive aspergillosis, voriconazole is significantly more effective compared to amphotericin B desoxycholate.

Related Organizations
Keywords

Antifungal Agents, Pyrimidines, Candidiasis, Aspergillosis, Humans, Microbial Sensitivity Tests, Mitosporic Fungi, Voriconazole, Triazoles

  • BIP!
    Impact byBIP!
    citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    9
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Top 10%
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
citations
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
9
Average
Top 10%
Average
Upload OA version
Are you the author of this publication? Upload your Open Access version to Zenodo!
It’s fast and easy, just two clicks!